MD1374G2 - Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică - Google Patents
Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceuticăInfo
- Publication number
- MD1374G2 MD1374G2 MD96-0296A MD960296A MD1374G2 MD 1374 G2 MD1374 G2 MD 1374G2 MD 960296 A MD960296 A MD 960296A MD 1374 G2 MD1374 G2 MD 1374G2
- Authority
- MD
- Moldova
- Prior art keywords
- monoclonal
- immunostimulatin
- antibodies
- obtaining
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Detergent Compositions (AREA)
Abstract
Invenţia se referă la medicină şi anume la imunoterapie.Esenţa invenţiei constă în aceea că anticorpul monoclonal imunostimulator sau fragmentul lui legând un antigen, careá legându-se cu celulele B limfoblastoide, induce proliferarea şi activarea limfocitelor sângelui periferic, asigură efectul antitumoral. Anticorpul propus se obţine prin imunizarea animalului cu un imunogen selectat din grupul constituit din celule B limfoblastoide, celule B limfoblastoide lizate sau preparate membranoase din ele, dezvoltarea ulterioară a reacţiei imune la animalul imunizat, extragerea limfocitelor B, creşterea, imortalizarea şi selectarea liniilor celulare, care secretează anticorpul revendicat. De asemenea, se declară linia celulară a hibridomului, depozitat în CNCM sub nr. 1-1397. Se propune o metodă de tratare a maladiilor, care include administrarea unei cantităţi eficiente de anticorp monoclonal propus. Se revendică o compoziţie farmaceutică, ce include în calitate de ingredient activ anticorpul monoclonal imunostimulator indicat. În plus, compoziţia farmaceutică poate suplimentar să conţină un agent care sporeşte activitatea limfocitelor citotoxice.Rezultatul este proliferarea şi activarea limfocitelor, asigurând efectul antitumoral.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL10850194A IL108501A (en) | 1994-01-31 | 1994-01-31 | Antibodies and pharmaceutical compositions containing them |
PCT/US1995/001137 WO1995020605A1 (en) | 1994-01-31 | 1995-01-30 | Immuno-stimulatory monoclonal antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
MD1374F2 MD1374F2 (ro) | 1999-12-31 |
MD1374G2 true MD1374G2 (ro) | 2000-09-30 |
Family
ID=11065761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MD96-0296A MD1374G2 (ro) | 1994-01-31 | 1995-01-30 | Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică |
Country Status (20)
Country | Link |
---|---|
US (1) | US5897862A (ro) |
EP (1) | EP0742795B1 (ro) |
JP (1) | JP3478398B2 (ro) |
CN (1) | CN1052733C (ro) |
AT (1) | ATE171461T1 (ro) |
AU (1) | AU693526B2 (ro) |
CA (1) | CA2182289C (ro) |
DE (1) | DE69504955T2 (ro) |
DK (1) | DK0742795T3 (ro) |
EE (1) | EE03285B1 (ro) |
ES (1) | ES2124533T3 (ro) |
FI (1) | FI963004A (ro) |
IL (1) | IL108501A (ro) |
LT (1) | LT4225B (ro) |
LV (1) | LV11624B (ro) |
MD (1) | MD1374G2 (ro) |
MX (1) | MX9603080A (ro) |
NO (1) | NO317020B1 (ro) |
RU (1) | RU2155190C2 (ro) |
WO (1) | WO1995020605A1 (ro) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD3972C2 (ro) * | 2009-03-11 | 2010-07-31 | Ион МЕРЕУЦЭ | Remediu şi metodă de tratament al stărilor precanceroase |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL129299A0 (en) * | 1999-03-31 | 2000-02-17 | Mor Research Applic Ltd | Monoclonal antibodies antigens and diagnosis of malignant diseases |
IL145926A0 (en) | 2001-10-15 | 2002-07-25 | Mor Research Applic Ltd | Peptide epitopes of mimotopes useful in immunomodulation |
IL149820A0 (en) * | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
ATE481985T1 (de) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
DE10311248A1 (de) * | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper |
WO2006021955A2 (en) * | 2004-08-23 | 2006-03-02 | Mor Research Applications Ltd. | Use of bat monoclonal antibody for immunotherapy |
EP1896582A4 (en) | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES FOR PROGRAMMED DEATH 1 (MP-1) AND METHODS FOR TREATING CANCER USING ANTI-MP-1 ANTIBODIES ALONE OR ASSOCIATED WITH OTHER IMMUNOTHERAPIES |
CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
PL2170959T3 (pl) | 2007-06-18 | 2014-03-31 | Merck Sharp & Dohme | Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1 |
RU2531758C2 (ru) * | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
WO2013014668A1 (en) | 2011-07-24 | 2013-01-31 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
US9580504B1 (en) | 2013-11-07 | 2017-02-28 | Curetech Ltd. | Pidilizumab monoclonal antibody therapy following stem cell transplantation |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
AU2016298227B9 (en) | 2015-07-30 | 2019-10-31 | Macrogenics, Inc. | PD-1-binding molecules and methods of use thereof |
BR112018003186A2 (pt) | 2015-09-01 | 2018-09-25 | Agenus Inc. | anticorpos anti-pd-1 e seus métodos de uso |
CA2997963A1 (en) | 2015-09-29 | 2017-04-06 | Celgene Corporation | Pd-1 binding proteins and methods of use thereof |
MX2018005550A (es) | 2015-11-03 | 2019-07-18 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a tim-3 y sus usos. |
CR20180318A (es) | 2015-12-14 | 2018-09-19 | Macrogenics Inc | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas |
CA3026474A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
EA201990747A1 (ru) | 2016-09-19 | 2019-10-31 | Способы лечения иммунных нарушений с применением белков, связывающих pd–1 | |
JP2019534859A (ja) | 2016-09-19 | 2019-12-05 | セルジーン コーポレイション | Pd−1結合タンパク質を使用して白斑を治療する方法 |
CN110300599A (zh) | 2016-12-07 | 2019-10-01 | 艾吉纳斯公司 | 抗体和其使用方法 |
GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5182368A (en) * | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
-
1994
- 1994-01-31 IL IL10850194A patent/IL108501A/en not_active IP Right Cessation
-
1995
- 1995-01-30 EE EE9600107A patent/EE03285B1/xx unknown
- 1995-01-30 RU RU96116984/13A patent/RU2155190C2/ru active
- 1995-01-30 CN CN95192406A patent/CN1052733C/zh not_active Expired - Lifetime
- 1995-01-30 CA CA002182289A patent/CA2182289C/en not_active Expired - Lifetime
- 1995-01-30 DK DK95910891T patent/DK0742795T3/da active
- 1995-01-30 EP EP95910891A patent/EP0742795B1/en not_active Expired - Lifetime
- 1995-01-30 US US08/380,857 patent/US5897862A/en not_active Expired - Lifetime
- 1995-01-30 DE DE69504955T patent/DE69504955T2/de not_active Expired - Lifetime
- 1995-01-30 MD MD96-0296A patent/MD1374G2/ro unknown
- 1995-01-30 AT AT95910891T patent/ATE171461T1/de active
- 1995-01-30 AU AU18686/95A patent/AU693526B2/en not_active Expired
- 1995-01-30 ES ES95910891T patent/ES2124533T3/es not_active Expired - Lifetime
- 1995-01-30 WO PCT/US1995/001137 patent/WO1995020605A1/en not_active Application Discontinuation
- 1995-01-30 JP JP52021095A patent/JP3478398B2/ja not_active Expired - Lifetime
-
1996
- 1996-07-29 FI FI963004A patent/FI963004A/fi unknown
- 1996-07-29 MX MX9603080A patent/MX9603080A/es not_active IP Right Cessation
- 1996-07-29 NO NO19963168A patent/NO317020B1/no not_active IP Right Cessation
- 1996-07-30 LT LT96-115A patent/LT4225B/lt not_active IP Right Cessation
- 1996-09-06 LV LVP-96-317A patent/LV11624B/en unknown
Non-Patent Citations (13)
Title |
---|
Clark, E. A, and Ledbetter, J.a. Amplification of the immune response by agonistic antibodies, Immunology Today. 1986, vol. 7, №9, p. 267-270; * |
Ellenhorn, Joshua D. et al. In vivo administration of an anti-CD3 prevents malignant progressor tumor growth. Science (Washington, D.C.). 1988, vol. 242, p. 569-571; * |
Gallinger, Steven et al. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice. Cancer Research. 1990, vol. 50, p. 2476-2480; * |
Hardy, Britta et al. A monoclonal antibody to human B lymphoblastoid cells activates human and murine T lymphocytes. Cellular Immunology. 1989, vol. 118, p.22-29 * |
Jenkins, Mars K. et al. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. The Journal of Immunology. 1991, vol.147, №8, p.2461-2466; * |
Jung, Gundram et al. Induction of cytotoxicity in human peripheral blood mononuclear cells by monoclonal antibody OKT3. The Journal of Immunology. 1987, vol.139, №2, p. 639-644; * |
Ledbetter, Jeffrey A. et al. Antibodies to Tp67 andTp44 augment and sustain proliferation responses of activated T cell. The Journal of Immunology. 1985, vol. 135, №4, p. 2331-2336; * |
Meuer, Stefan C. et al. Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin-2 dependent autocrine pathway. Proc. Natl. Acad. Sci. USA, 1984, vol. 81, p. 1509-1513; * |
Moretta Alessandro et al. CD69-mediated pathway of lymphocyte activation: anti- CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor (/(. J. Exp. Med., 1991, vol. 174, p.1393-1398; * |
Townsend, Sarah E. et al. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (Washington, D.C.). 1993, vol. 259, p.368-370; * |
Van Lier, R., et al. Studies on the monocyte dependence of T-cell proliferation induced by monoclonal antibodies directed against region I and II of the CD2 antigen. Immunology, 1989, vol. 67, p. 333-338; * |
Van Lier, Rene( A. W. et al. Signals involved in T cell activation. T cell proliferation induced through the synergistic action of anti-CD28 and anti-CD2 monoclonal antibodies Eur. J. Immunol. 1998, vol. 18, p. 167-172; * |
Van Wauwe, Jean P.,et al. OKT3: a monoclonal anti-human T lymphocyte antibody and potent mitogenic properties. The Journal of Immunology. 1980, vol. 124, №6, p. 2708-2713; * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD3972C2 (ro) * | 2009-03-11 | 2010-07-31 | Ион МЕРЕУЦЭ | Remediu şi metodă de tratament al stărilor precanceroase |
Also Published As
Publication number | Publication date |
---|---|
NO963168L (no) | 1996-09-27 |
CN1145077A (zh) | 1997-03-12 |
LV11624A (en) | 1996-12-20 |
FI963004A (fi) | 1996-09-27 |
EE03285B1 (et) | 2000-08-15 |
JP3478398B2 (ja) | 2003-12-15 |
DK0742795T3 (da) | 1999-06-14 |
EP0742795B1 (en) | 1998-09-23 |
AU1868695A (en) | 1995-08-15 |
DE69504955T2 (de) | 1999-05-27 |
EP0742795A1 (en) | 1996-11-20 |
MD1374F2 (ro) | 1999-12-31 |
AU693526B2 (en) | 1998-07-02 |
MX9603080A (es) | 1998-01-31 |
IL108501A (en) | 1998-10-30 |
IL108501A0 (en) | 1994-05-30 |
US5897862A (en) | 1999-04-27 |
NO963168D0 (no) | 1996-07-29 |
CA2182289A1 (en) | 1995-08-03 |
NO317020B1 (no) | 2004-07-26 |
ES2124533T3 (es) | 1999-02-01 |
CA2182289C (en) | 2003-10-21 |
ATE171461T1 (de) | 1998-10-15 |
FI963004A0 (fi) | 1996-07-29 |
JPH09508390A (ja) | 1997-08-26 |
LT4225B (en) | 1997-10-27 |
CN1052733C (zh) | 2000-05-24 |
RU2155190C2 (ru) | 2000-08-27 |
LV11624B (en) | 1997-06-20 |
LT96115A (en) | 1997-05-26 |
WO1995020605A1 (en) | 1995-08-03 |
DE69504955D1 (de) | 1998-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD1374G2 (ro) | Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică | |
ATE212038T1 (de) | Humanisierte monoklonale anti-cd40 antikörper und fragmente zur hemmung der b-zellaktivierung | |
HUP0200537A2 (en) | Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases | |
WO2003099196A3 (en) | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency | |
HU9203370D0 (en) | Humanized chimaeric anti-icam-1 antibodies and method for producing them | |
NZ508381A (en) | Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5) | |
IE890720L (en) | Improvements relating to antigens | |
IL140138A (en) | Specific antibodies of tie-2 ligands | |
AU3125289A (en) | Monoclonal antibodies directed against human tumor necrosis factor - receptor | |
ATE233102T1 (de) | Verfahren und zusammensetzung zur umgestaltung multi-epitopischer antigene um die immunantwort einzuleiten | |
AU2002223462A1 (en) | Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28 | |
EP0194851A3 (en) | Human tumor therapy | |
AU2070688A (en) | Antigen recognized by mca 16-88 | |
WO1999043815A3 (en) | Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof | |
NO924803L (no) | Tumor-relatert monoklonalt antistoff 88bv59 | |
AU4775899A (en) | Human monoclonal antibodies against the tumor antigen uk114 and lymphocyte cellsand hybridomas for their production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD99 | Pending application |